Literature DB >> 479671

A solid-phase radioimmunoassay for bound anti-platelet antibody: studies on 45 patients with autoimmune platelet disorders.

K Hymes, S Shulman, S Karpatkin.   

Abstract

A highly sensitive, solid-phase radioimmunoassay has been developed for detecting platelet-bound immunoglobulin, which employs 125I-staphylococcal protein A. The assay detects platelet IgG at the picogram level, which is 10- to 50-fold more sensitive than currently available procedures. It is relatively simple and can be performed on frozen extracts from as little as 2 X 10(5) platelets. Washed platelets are frozen, thawed, sonicated, and centrifuged at 20,000 X g. The supernatant, which contains 7S IgG, is applied in serial dilution to the wells of a plastic microliter plate capable of adsorbing protein. Commercial rabbit anti-human IgG is added and then "sandwiched" to 125I-staphylococcal protein A. The wells are removed from the plate and assayed for radioactivity. Thirty-two of 35 thrombocytopenic patients (92%) with ATP had platelet IgG values greater than those of controls by 2 S.D. and averaged 150 +/- 145 (S.D.) ng/10(6) platelets; 11 healthy controls, 11.4 +/- 7.4 ng; five "thrombocytopenic" controls, 9.7 +/- 13 ng. The platelet count (X) correlated inversely with IgG/platelet (Y) according to the equation: Log Y = -0.66 log X + 4.8; r = -0.71, p less than 0.001. Elevated platelet IgG levels were also found in 5 ATP patients in "apparent remission"; two of four had evidence for compensated thrombocytolysis (increased megathrombocytes). Elevated platelet IgG levels were also found in six patients with thrombocytopenia secondary to lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 479671

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  13 in total

1.  Association of increased immune complexes, platelet IgG and serum IgG in chronic active hepatitis.

Authors:  S L Pfueller; B G Firkin; N Kerlero de Rosbo; A Riglar; I R Mackay
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

2.  Reactions of immunoglobulin G-binding ligands with platelets and platelet-associated immunoglobulin G.

Authors:  W F Rosse; D V Devine; R Ware
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

3.  Platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura.

Authors:  J Winiarski; G Holm
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

4.  Platelet associated immunoglobulins in primary biliary cirrhosis: a cause of thrombocytopenia?

Authors:  M F Bassendine; J D Collins; J Stephenson; P Saunders; O F James
Journal:  Gut       Date:  1985-10       Impact factor: 23.059

5.  Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome.

Authors:  Z M Sthoeger; B Tartakovsky; Z Bentwich; E Mozes
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

6.  Relative importance of total versus external platelet-associated IgG.

Authors:  U E Nydegger; J P Buchs; L Borradori
Journal:  Blut       Date:  1989-07

7.  Idiopathic thrombocytopenia, initial illness and long term follow up.

Authors:  R W Walker; W Walker
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

8.  Circulating immune complexes and platelet IgG in various diseases.

Authors:  V Puram; D Giuliani; B S Morse
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

9.  Platelet-associated DNA and anti-DNA antibody in systemic lupus erythematosus with nephritis.

Authors:  G Frampton; S Perl; A Bennett; J S Cameron
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

10.  Anti-human immunodeficiency virus type 1 antibody complexes on platelets of seropositive thrombocytopenic homosexuals and narcotic addicts.

Authors:  S Karpatkin; M Nardi; E T Lennette; B Byrne; B Poiesz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.